Vytorin FDA Approval History
FDA Approved: Yes (First approved July 23, 2004)
Brand name: Vytorin
Generic name: ezetimibe/simvastatin
Dosage form: Tablets
Company: Merck/Schering-Plough Pharmaceuticals
Treatment for: High Cholesterol, Familial Heterozygous, High Cholesterol, Familial Homozygous
Vytorin (ezetimibe/simvastatin) is a combination of ezetimibe (a lipid-lowering compound) and simvastatin (an HMG-CoA reductase inhibitor) for the treatment of high LDL cholesterol (LDL-C) in patients with primary hypercholesterolemia or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.
Development timeline for Vytorin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.